- DIAGNOS (ADK) has entered into a Memorandum of Understanding (MoU) with Essilor International
- The MoU forms the basis of a potential distribution agreement with Essilor International for DIAGNOS’ CARA platform
- DIAGNOS has multiple new applications under development involving AI-enhanced retinal imaging
- DIAGNOS is a Canadian corporation dedicated to the early detection of critical health problems based on its FLAIRE Artificial Intelligence platform
- Diagnos Inc. (ADK) is up 1.85 per cent, trading at C$0.55 per share at 11:30 am ET
DIAGNOS (ADK) has entered into a Memorandum of Understanding (MoU) with the Instruments division of Essilor International, a subsidiary of EssilorLuxottica.
Essilor designs, manufactures and markets a wide range of lenses and diagnostic ophthalmic instruments.
The MoU forms the basis of a potential distribution agreement with Essilor International for DIAGNOS’ CARA platform, as well as of certain specified future developments of the CARA platform for a variety of applications.
DIAGNOS has multiple new applications under development involving AI-enhanced retinal imaging to address a growing need for general-purpose pathology identification. In addition to localized retinal pathology, such as macular degeneration and glaucoma, certain retinal pathologies are also known indicators of various systemic disorders, including cardiovascular and diabetic diseases.
On July 20, DIAGNOS announced a clinical trial with CommonSpirit Health Research Institute for the early detection of stroke through the inspection and analysis of the retina.
Mr. André Larente, President of DIAGNOS commented on the partnership with Essilor.
“DIAGNOS is focused on its commercialization strategy and pursuing opportunities with potential partners. We are very pleased that our AI-based technology has attracted the attention of global eyecare sector leaders such as Essilor International and we are looking forward to our discussions with respect to a mutually beneficial potential worldwide distribution agreement. At the same time, DIAGNOS continues to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure that we stay ahead of our competition worldwide.”
DIAGNOS is a Canadian corporation dedicated to the early detection of critical health problems based on its FLAIRE Artificial Intelligence platform.
FLAIRE allows for quick modifying and development of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images.
Diagnos Inc. (ADK) is up 1.85 per cent, trading at C$0.55 per share at 11:30 am ET.